OTCMKTS:ASCLF Ascletis Pharma (ASCLF) Stock Forecast, Price & News $0.34 -0.03 (-8.57%) (As of 05/18/2023) Add Compare Share Share Today's Range$0.34▼$0.3450-Day Range$0.31▼$0.6252-Week Range$0.31▼$0.62Volume1,000 shsAverage Volume2,670 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesShort InterestProfileChartCompetitorsHeadlinesShort Interest About Ascletis Pharma (OTCMKTS:ASCLF) StockAscletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.Read More Receive ASCLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ASCLF Stock News HeadlinesMay 8, 2023 | markets.businessinsider.comAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV InfectionMay 8, 2023 | finance.yahoo.comAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionMay 29, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 2, 2023 | finance.yahoo.comAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for AcneMay 1, 2023 | americanbankingnews.comAscletis Pharma Inc. (OTCMKTS:ASCLF) Sees Significant Decrease in Short InterestFebruary 27, 2023 | finance.yahoo.comAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech IndexJanuary 31, 2023 | finance.yahoo.comAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionJanuary 26, 2023 | finance.yahoo.comAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAMay 29, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>January 17, 2023 | msn.comSupply enters ritonavir tablets supply agreement with SimcereJanuary 16, 2023 | finance.yahoo.comAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with SimcereJanuary 15, 2023 | finance.yahoo.comAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19January 3, 2023 | msn.comViking Therapeutics sues Ascletis Pharma for stealing trade secretsDecember 20, 2022 | finance.yahoo.comAscletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as PlannedDecember 19, 2022 | finance.yahoo.comAscletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its DerivativesDecember 12, 2022 | markets.businessinsider.comAscletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19December 12, 2022 | finance.yahoo.comAscletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19December 7, 2022 | marketwatch.comAscletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical TrialDecember 7, 2022 | markets.businessinsider.comAscletis Pharma Announces IND Approval For ASC11 In China - Quick FactsDecember 7, 2022 | seekingalpha.comAscletis gets Chinese drug regulator nod to start trial of oral COVID therapyNovember 30, 2022 | finance.yahoo.comAscletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for AcneNovember 23, 2022 | markets.businessinsider.comAscletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19November 23, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDANovember 16, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPANovember 1, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19October 26, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox IndicationOctober 10, 2022 | seekingalpha.comWeek In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong ExchangeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASCLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ASCLF CUSIPN/A CIKN/A Webwww.ascletis.com PhoneN/AFaxN/AEmployees266Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesDr. Jinzi Jason Wu (Age 60)Founder, Chairman & CEO Dr. Handan He Ph.D. (Age 61)Chief Scientific Officer Ms. Hejingdao Wu (Age 49)Sr. VP of Operations & Exec. Director Ms. Yuemei Yan (Age 53)Sr. VP of Clinical Devel. Operations Dr. Kristjan Sigurdur Gudmundsson (Age 55)Sr. Consultant & Head of Discovery Dr. George Zhengzhi Hill (Age 72)Sr. Consultant & Chief Medical Advisor Mr. John P. Gargiulo M.B.A.Chief Bus. OfficerMr. Ming Fai Chung CPACompany Sec.More ExecutivesKey Competitors3SBioOTCMKTS:TRSBFAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAinosNASDAQ:AIMDWView All Competitors ASCLF Stock - Frequently Asked Questions How have ASCLF shares performed in 2023? Ascletis Pharma's stock was trading at $0.55 at the start of the year. Since then, ASCLF shares have decreased by 37.4% and is now trading at $0.3445. View the best growth stocks for 2023 here. Are investors shorting Ascletis Pharma? Ascletis Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 743,300 shares, an increase of 5.4% from the April 30th total of 705,000 shares. Based on an average trading volume of 4,200 shares, the days-to-cover ratio is currently 177.0 days. View Ascletis Pharma's Short Interest. What is Ascletis Pharma's stock symbol? Ascletis Pharma trades on the OTCMKTS under the ticker symbol "ASCLF." How do I buy shares of Ascletis Pharma? Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ascletis Pharma's stock price today? One share of ASCLF stock can currently be purchased for approximately $0.34. How many employees does Ascletis Pharma have? The company employs 266 workers across the globe. This page (OTCMKTS:ASCLF) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.